Valuation: enGene Therapeutics Inc.

Market Cap 132M 116M 110M 99.59M 187M 12.67B 188M 1.31B 508M 6.47B 496M 485M 20.78B P/E 2026 *
-1.08x
P/E 2027 * -1.25x
Enterprise Value -65.86M -57.93M -54.78M -49.68M -93.31M -6.32B -93.85M -656M -253M -3.23B -247M -242M -10.37B EV / Sales 2026 *
-
EV / Sales 2027 * -1.51x
Free-Float
99.9%
Yield 2026 *
-
Yield 2027 * -
1 day-2.44%
1 week+2.04%
Current month+8.70%
1 month+9.59%
3 months+14.29%
6 months-68.60%
Current year-77.85%
1 week 1.88
Extreme 1.875
2.05
1 month 1.76
Extreme 1.76
2.08
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Chief Tech/Sci/R&D Officer 55 24/04/2023
Director of Finance/CFO 48 16/07/2026
Director TitleAgeSince
Director/Board Member 57 08/08/2023
Director/Board Member 66 18/12/2023
Director/Board Member 66 15/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
22/9/26 Buy

Chief Technology Officer

5,102 0.0076%
16/7/26 Other

Interim Chief Business Officer

75,000 0.1120%
16/7/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-2.44%+2.04%-69.18%-81.82% 132M
-0.37%-3.67%+57.21%+87.75% 71.81B
-0.07%-2.70%+37.74%+86.90% 60.06B
+0.19%+1.04%+34.34%+16.54% 27.93B
-0.14%-2.75%-14.13%+356.79% 25.7B
+0.57%+1.10%+1.02%-2.89% 24.89B
+1.10%+1.86%+25.07%-7.59% 20.92B
-1.70%+0.43%+150.24%+323.16% 15.04B
+0.36%+2.01%+49.51%+160.70% 14.46B
+4.96%-2.49%-3.55%+524.02% 13.87B
Average +0.19%-0.90%+26.83%+146.36% 27.48B
Weighted average by Cap. +0.15%-1.91%+37.98%+128.68%

Financials

2026 *2027 *
Net sales - 6.17M 5.43M 5.13M 4.65M 8.74M 592M 8.79M 61.44M 23.73M 302M 23.17M 22.66M 971M
Net income -124M -109M -103M -93.61M -176M -11.91B -177M -1.24B -477M -6.08B -466M -456M -19.53B -121M -107M -101M -91.58M -172M -11.65B -173M -1.21B -467M -5.95B -456M -446M -19.11B
Net Debt -198M -174M -165M -149M -280M -19B -282M -1.97B -761M -9.69B -743M -727M -31.15B -141M -124M -118M -107M -200M -13.56B -201M -1.41B -543M -6.92B -531M -519M -22.24B
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs. The Company's lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene at high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene is being developed using its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
28/09/26 USD 1.970 +0.51% 332,186
25/09/26 USD 1.960 +2.08% 1,976,168
24/09/26 USD 1.920 -4.00% 796,304
23/09/26 USD 2.000 -2.44% 669,455
22/09/26 USD 2.050 +4.59% 1,066,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
1.970USD
Average target price
3.286USD
Spread / Average Target
+66.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENGN Stock